Vllahu M, Savarese M, Cantiello I, Munno C, Sarcina R, Stellato P
Biomedicines. 2025; 13(2).
PMID: 40002837
PMC: 11852417.
DOI: 10.3390/biomedicines13020424.
Erbilgin Y, Firtina S, Kirat E, Khodzhaev K, Karakas Z, Unuvar A
Biochem Genet. 2025; .
PMID: 39786526
DOI: 10.1007/s10528-024-11018-7.
Pan L, Chen Y, Weng K, Guo B, Zhuang S, Huang S
BMC Cancer. 2024; 24(1):1070.
PMID: 39210321
PMC: 11363382.
DOI: 10.1186/s12885-024-12828-z.
de Albuquerque A, Lopes B, Fernandes R, Gimba E, Emerenciano M
Hematol Transfus Cell Ther. 2024; 46 Suppl 6:S163-S170.
PMID: 39095315
PMC: 11726076.
DOI: 10.1016/j.htct.2024.05.004.
Kastner P, Chan S
Adv Exp Med Biol. 2024; 1459:33-52.
PMID: 39017838
DOI: 10.1007/978-3-031-62731-6_2.
Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines.
Nishiguchi G, Mascibroda L, Young S, Caine E, Abdelhamed S, Kooijman J
Nat Commun. 2024; 15(1):482.
PMID: 38228616
PMC: 10791743.
DOI: 10.1038/s41467-024-44698-1.
Constitutively active CaMKII Drives B lineage acute lymphoblastic leukemia/lymphoma in tp53 mutant zebrafish.
Rothschild S, Lai G, Tombes R, Clements W
PLoS Genet. 2023; 19(12):e1011102.
PMID: 38117861
PMC: 10766190.
DOI: 10.1371/journal.pgen.1011102.
Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia.
Kimura H, Onozawa M, Yoshida S, Miyashita N, Yokoyama S, Matsukawa T
Ann Hematol. 2023; 102(11):3103-3113.
PMID: 37597110
DOI: 10.1007/s00277-023-05405-0.
Association of IKZF1 and CDKN2A gene polymorphisms with childhood acute lymphoblastic leukemia: a high-resolution melting analysis.
Sattarzadeh Bardsiri M, Zehtab S, Karami N, Farsinejad A, Ehsan M, Fatemi A
BMC Med Genomics. 2022; 15(1):171.
PMID: 35932035
PMC: 9354342.
DOI: 10.1186/s12920-022-01325-6.
The telomere complex and the origin of the cancer stem cell.
Torres-Montaner A
Biomark Res. 2021; 9(1):81.
PMID: 34736527
PMC: 8567692.
DOI: 10.1186/s40364-021-00339-z.
Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities.
Rogers J, Gupta R, Reyes J, Gundry M, Medrano G, Guzman A
Blood Adv. 2021; 5(19):3876-3890.
PMID: 34492683
PMC: 8679666.
DOI: 10.1182/bloodadvances.2020002408.
Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.
Nishiguchi G, Keramatnia F, Min J, Chang Y, Jonchere B, Das S
J Med Chem. 2021; 64(11):7296-7311.
PMID: 34042448
PMC: 8201443.
DOI: 10.1021/acs.jmedchem.0c01313.
Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
Ge Z, Song C, Ding Y, Tan B, Desai D, Sharma A
Leukemia. 2021; 35(5):1267-1278.
PMID: 33531656
PMC: 8102195.
DOI: 10.1038/s41375-021-01132-5.
IKAROS-Associated Diseases in 2020: Genotypes, Phenotypes, and Outcomes in Primary Immune Deficiency/Inborn Errors of Immunity.
Kuehn H, Nunes-Santos C, Rosenzweig S
J Clin Immunol. 2021; 41(1):1-10.
PMID: 33392855
DOI: 10.1007/s10875-020-00936-x.
Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.
Giebel S, Labopin M, Socie G, Beauvais D, Klein S, Wagner-Drouet E
Bone Marrow Transplant. 2020; 56(5):1047-1055.
PMID: 33235351
DOI: 10.1038/s41409-020-01139-z.
Ikaros antagonizes DNA binding by STAT5 in pre-B cells.
Heizmann B, Le Gras S, Simand C, Marchal P, Chan S, Kastner P
PLoS One. 2020; 15(11):e0242211.
PMID: 33180866
PMC: 7660478.
DOI: 10.1371/journal.pone.0242211.
Integration of high-throughput reporter assays identify a critical enhancer of the Ikzf1 gene.
Alomairi J, Molitor A, Sadouni N, Hussain S, Torres M, Saadi W
PLoS One. 2020; 15(5):e0233191.
PMID: 32453736
PMC: 7250416.
DOI: 10.1371/journal.pone.0233191.
IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.
Song C, Ge Z, Ding Y, Tan B, Desai D, Gowda K
Blood. 2020; 136(13):1520-1534.
PMID: 32396934
PMC: 7515690.
DOI: 10.1182/blood.2019002655.
EOS, an Ikaros family zinc finger transcription factor, interacts with the HTLV-1 oncoprotein Tax and is downregulated in peripheral blood mononuclear cells of HTLV-1-infected individuals, irrespective of clinical statuses.
Naito T, Ushirogawa H, Fukushima T, Tanaka Y, Saito M
Virol J. 2019; 16(1):160.
PMID: 31856855
PMC: 6923961.
DOI: 10.1186/s12985-019-1270-1.
A long hypoxia-inducible factor 3 isoform 2 is a transcription activator that regulates erythropoietin.
Tolonen J, Heikkila M, Malinen M, Lee H, Palvimo J, Wei G
Cell Mol Life Sci. 2019; 77(18):3627-3642.
PMID: 31768607
PMC: 7452874.
DOI: 10.1007/s00018-019-03387-9.